News

Iovance Biotherapeutics, Inc.: Iovance Biotherapeutics Reports Financial Results and Corporate Updates for First Quarter 2025
Q25 Total Product Revenue of $49.3M FY25 Total Product Revenue Guidance Revised to $250M-$300M FY25 Operating Expenses Reduced and 2H26 Cash Runway Guidance Maintained 2025 Regulatory Approvals for ...
Cabaletta Bio Inc.
Catherine Bollard is the founder of Mana Therapeutics, Inc. Current jobs include Program Director at Children's National Hospital (District of Columbia) since 2013, Director at Alliance for ...
Bio-Techne outlines 2025 growth drivers with NIH uncertainty and strong Protein Sciences performance
Techne's Q3 2025 earnings call, including 6% organic growth, FDA-driven opportunities, and strategies to tackle NIH funding & ...
BioCryst: Strong Opportunity For A Double With A Proven Therapy
BioCryst Pharma's ORLADEYO leads HAE market growth, with strong financial performance and potential despite rising ...